This document summarizes a study on the 5-year survival of non-small cell lung cancer patients after adjuvant chemoimmunoradiotherapy compared to surgery alone or postoperative radiotherapy. The study found that adjuvant chemoimmunoradiotherapy significantly improved 5-year survival and lifespan for patients with lymph node metastases (N1-2) compared to the other treatments. However, for patients without lymph node metastases (N0), the 5-year survival was not significantly different between adjuvant chemoimmunoradiotherapy and surgery alone or postoperative radiotherapy.

1. 5-Year Survival of Non-Small Cell Lung Cancer Patients after Adjuvant Chemoimmunoradiotherapy Oleg Kshivets, M.D., Ph.D. Department of Surgery, Siauliai Public Hospital, Lithuania The 53 rd Annual Cancer Symposium of Society of Surgical Oncology New Orleans, The USA, 2000

7. 5-Year Survivors and Losts

8. Results of Factor Analysis

9. Results of Factor Analysis

10. Nucloids of Lung Cancer Patients with N0-2, n=404

11. Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N0-2, n=404

12. Nucloids of Lung Cancer Patients with N1-2, n=181

13. Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N1-2, n=181

14. Network-Model of Lung Cancer Patients with N0-2 (n=404)

15. Network-Model of Lung Cancer Patients with N0 (n=223)

16. Network-Model of Lung Cancer Patients with N1-2 (n=181)

17. Survival of Lung Cancer Patients with N0-2 (n=404)

18. Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N0-2, n=404

19. Logistic Regression Model of Lung Cancer Patients with N0-2, n=404

20. Logistic Regression Model of Lung Cancer Patients with N0-2, n=404

21. SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N0-2 metastases (n=404)

22. Survival of Lung Cancer Patients with N0-2 (n=404)

23. Survival of Lung Cancer Patients with N1-2 (n=181)

24. Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N1-2, n=181

25. Logistic Regression Model of Lung Cancer Patients with N1-2, n=181

26. Logistic Regression Model of Lung Cancer Patients with N1-2, n=181

27. SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N1-2 metastases (n=181)

28. Results of Monte Carlo Simulation

29. Life Span of Died Lung Cancer Patients with N0-2 (n=162)